Deep Vein Thrombosis Clinical Trial
— PACTOfficial title:
Physical Activity in Children at Risk of Post-thrombotic Sequelae: A Pilot Randomized Controlled Trial
Verified date | March 2021 |
Source | University of Texas Southwestern Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
'The PACT trial' is randomized pilot trial to demonstrate the feasibility and potential effectiveness of a personal "fitness tracker" to improve adherence to an activity regimen following an initial acute DVT in children.
Status | Completed |
Enrollment | 111 |
Est. completion date | October 10, 2019 |
Est. primary completion date | October 9, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 7 Years to 21 Years |
Eligibility | Inclusion Criteria: - A radiologically confirmed, acute, proximal first lower extremity DVT - 4 to 8 weeks after starting anticoagulation - Out-patient ambulatory status Exclusion Criteria: - Contraindication to increasing activity such as patients with juvenile arthritis, poor balance, congestive heart failure, etc. |
Country | Name | City | State |
---|---|---|---|
United States | Children's Medical Center | Dallas | Texas |
Lead Sponsor | Collaborator |
---|---|
University of Texas Southwestern Medical Center | National Heart, Lung, and Blood Institute (NHLBI), Texas Scottish Rite Hospital for Children |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feasibility as Measured by Number of Participants Who Meet Study Eligibility Criteria at Baseline | Feasibility criteria for rate of study eligibility met when assessed to be = 30%
INCLUSION CRITERIA: 1.) Age 7-21 years 2.)2. A radiologically confirmed, acute, proximal (iliofemoral and femoropopliteal) first lower extremity DVT and/or confirmed, acute pulmonary embolism (unilateral or bilateral) 3.) 12 weeks (±2 weeks) after starting anticoagulation 4.) Out-patient ambulatory status |
Baseline | |
Primary | Number of Screened Subjects Who Provided Consent at Baseline | Feasibility criteria for rate of consent was assessed to be = 30% at baseline
INCLUSION CRITERIA: 1.) Age 7-21 years 2.)2. A radiologically confirmed, acute, proximal (iliofemoral and femoropopliteal) first lower extremity DVT and/or confirmed, acute pulmonary embolism (unilateral or bilateral) 3.) 12 weeks (±2 weeks) after starting anticoagulation 4.) Out-patient ambulatory status |
Baseline | |
Primary | Mean Number of Participants Who Adhered to the Assigned Physical Activity During 8-week Period (Intervention Arm -FitBit Arm ) | Adherence in the physical activity group is calculated based on the number of participants who complied with the target weekly goal or activity prescription during the "active" 8-week period. | 8 weeks | |
Primary | Mean Physical Activity Questionnaire Score at 3 Months (Standard of Care Arm Only) | The Godin-Shephard Leisure-Time Physical Activity Questionnaire was used to quantify physical activity levels. Individuals reporting moderate-to-strenuous activity levels =24 were classified as active (better outcome), whereas individuals reporting moderate-to-strenuous activity levels =23 were classified were insufficiently active (worse outcome). | 3 months | |
Primary | Mean Physical Activity Questionnaire Score at 6 Months (Standard of Care Arm Only) | The Godin-Shephard Leisure-Time Physical Activity Questionnaire was used to quantify physical activity levels. Individuals reporting moderate-to-strenuous activity levels =24 were classified as active (better outcome), whereas individuals reporting moderate-to-strenuous activity levels =23 were classified were insufficiently active (worse outcome). | 6 months | |
Primary | Mean Physical Activity Questionnaire Score at 9 Months (Standard of Care Arm Only) | The Godin-Shephard Leisure-Time Physical Activity Questionnaire was used to quantify physical activity levels. Individuals reporting moderate-to-strenuous activity levels =24 were classified as active (better outcome), whereas individuals reporting moderate-to-strenuous activity levels =23 were classified were insufficiently active (worse outcome). | 9 months | |
Primary | Proportion of Subjects Who Complete Post-randomization | Feasibility criteria is met when assessed to be = 80%. This includes the number of subjects who successfully completed the trial. | Within 24 months of trial initiation | |
Secondary | Change in PTS Biomarkers (D-dimer) | Change in PTS biomarkers from baseline to post intervention of increased physical activity measured by coagulation activation marker D-dimer. | From baseline to 6 months | |
Secondary | Percentage Change From Baseline in FVIII PTS Biomarker | Change in PTS biomarkers from baseline to post intervention of increased physical activity measured by the coagulation activation marker FVIII | From baseline to 6 month | |
Secondary | Change in PTS Biomarkers (C-reactive Protein) | Change in PTS biomarkers from baseline to post intervention of increased physical activity measured by inflammation marker C-reactive protein (CRP) using a latex-enhanced immunoturbidimetric assay. | From baseline to 6 month | |
Secondary | Change in PTS Biomarkers (Fibrinolysis - Endogenous Thrombin Potential) | Change in PTS biomarkers from baseline to post intervention of increased physical activity measured by endogenous thrombin potential using calibrated automated thrombogram (CAT). CAT is a routine test that measures hyper- and hypocoagulability. | From baseline to 6 month | |
Secondary | Change in PTS Biomarkers (Fibrinolysis - Thrombin Generation) | Change in PTS biomarkers from baseline to post intervention of increased physical activity measured by thrombin generation assay using calibrated automated thrombogram (CAT). CAT is a routine test that measures hyper- and hypocoagulability. | From baseline to 6 month | |
Secondary | Percent Change in Fibrinolysis Biomarker | Percent Change in Fibrinolysis Biomarker from baseline to post intervention of increased physical activity is measured by thromboelastography (TEG). TEG is often used to predict bleeding and diagnose various bleeding disorders.
Lysis 30% and Lysis 60% are measurements of percent amplitude reduction 30 and 60 minutes after maximum amplitude, respectively, on thromboelastography. Decreased clotting ability (negative value) = better outcome Increased clotting ability (positive value)= worse outcome |
From baseline to 6 month | |
Secondary | Change in Quality of Life | Change in Quality of Life from baseline to post intervention of increased physical activity assessed by PedsQL instrument. It consists of structured interview with the parents and the child with 23 items divided among 4 sub-scales to assess function in 4 domains: Physical; Emotional; social; and School. Each item is a statement of a problem, which the subject rates in severity from 0-4, indicating a problem never occurs (score of 0) to almost always occurs (score of 4). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50,3=25,4=0, with higher scores indicating better health related QoL.
The positive change from baseline to 6 months correspond to better quality of life. |
From baseline to 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05003843 -
BOLT: Study of the Indigo® Aspiration System When Used in Patients With Deep Vein Thrombosis
|
N/A | |
Recruiting |
NCT03937947 -
Traumatic Brain Injury Associated Radiological DVT Incidence and Significance Study
|
||
Withdrawn |
NCT04136561 -
Novel Strategy to Encourage Early Removal of Central Venous Catheters
|
N/A | |
Completed |
NCT03420625 -
Blood Flow Stimulation in the Lower Limbs by Application of Different External Devices
|
N/A | |
Recruiting |
NCT02507180 -
Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
|
||
Completed |
NCT02555111 -
Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis.
|
Phase 3 | |
Terminated |
NCT02469376 -
Evaluation of a New Imagingtechnologie for Thrombosis
|
Phase 1 | |
Completed |
NCT01975090 -
The SENTRY Clinical Study
|
N/A | |
Completed |
NCT02037607 -
Incidence of Venous Thromboembolism in Children Undergoing Elective Neurosurgical Procedures
|
N/A | |
Not yet recruiting |
NCT01357941 -
Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE)
|
N/A | |
Completed |
NCT00771303 -
Ruling Out Pulmonary Embolism During Pregnancy:a Multicenter Outcome Study
|
||
Completed |
NCT00720915 -
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
|
N/A | |
Completed |
NCT00773448 -
Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism
|
N/A | |
Completed |
NCT00244725 -
Odiparcil For The Prevention Of Venous Thromboembolism
|
Phase 2 | |
Completed |
NCT00264277 -
D-dimer to Establish Duration of Anticoagulation After Venous Thromboembolism
|
Phase 4 | |
Completed |
NCT00365950 -
3 Months' Versus 6 Months' Anticoagulation in Patients With DVT and/or PE
|
Phase 4 | |
Completed |
NCT00182403 -
Fixed Dose Heparin Study
|
Phase 3 | |
Completed |
NCT03682419 -
Evaluation of Precision and Accuracy of INR Measurements in a Point of Care Device (OPTIMAL)
|
N/A | |
Not yet recruiting |
NCT04981327 -
The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis
|
Phase 3 | |
Recruiting |
NCT03240120 -
A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism
|
Phase 3 |